CellaVision AB (CHIX:CEVIs)

Q4 2025 CellaVision AB Earnings Call Transcript

Feb 5, 2026 / 10:00 AM GMT

Release Date Price: kr160.2

Transcript

Key Points

Positve

CellaVision AB (CLVSF) reported a 5.6% increase in net sales for Q4 2025, translating to an organic growth of 12.2%.
The company achieved a significant milestone by obtaining CE mark for its new bone marrow aspirate application, allowing for its launch in the EU.
Strong performance in the Americas, particularly in the US, with an all-time high revenue of SEK 90 million, representing an organic growth of 50%.
The board of directors proposed an increase in dividends from SEK 2.5 to SEK 2.75 per share.
CellaVision AB (CLVSF) successfully validated a significant software upgrade for its hematology instruments, enhancing user experience and operational speed.

Negative

The APEC region experienced a soft quarter with an organic decline of 40%, attributed to a strong comparable quarter from the previous year.
Gross margin decreased to 67%, impacted by software and FX effects.
R&D spending was down to SEK 37 million, a 9% decrease year-over-year, due to project phase changes and reduced consultant use.
The company faced challenges with non-hematology product lines, which slightly reduced overall organic growth.
The software and others segment experienced declining growth, partly due to currency effects and a large tender in the previous year.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CEVI.ST - CellaVision AB
Q4 2025 CellaVision AB Earnings Call
Feb 05, 2026 / 10:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to Celevision Q4 report 2025. For the first part of the conference call, the participants will be in listen-only mode. During the questions and answer session, participants are able to ask questions by dialing pound 5 on their telephone keypad. Now I will hand the conference over to CEO Simon Ostergaard. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you very much and thank you very much out there for dialing in for television's quarterly report Q4 2025 which obviously also includes the consolidated results from the entire 2025.

A lot of good things

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.